JP2013523082A5 - - Google Patents

Download PDF

Info

Publication number
JP2013523082A5
JP2013523082A5 JP2012543839A JP2012543839A JP2013523082A5 JP 2013523082 A5 JP2013523082 A5 JP 2013523082A5 JP 2012543839 A JP2012543839 A JP 2012543839A JP 2012543839 A JP2012543839 A JP 2012543839A JP 2013523082 A5 JP2013523082 A5 JP 2013523082A5
Authority
JP
Japan
Prior art keywords
peptide
isolated
apc
group
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012543839A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013523082A (ja
JP5816965B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2011/001909 external-priority patent/WO2011122022A1/en
Publication of JP2013523082A publication Critical patent/JP2013523082A/ja
Publication of JP2013523082A5 publication Critical patent/JP2013523082A5/ja
Application granted granted Critical
Publication of JP5816965B2 publication Critical patent/JP5816965B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012543839A 2010-04-02 2011-03-30 Ect2ペプチドおよびそれを含むワクチン Active JP5816965B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32057710P 2010-04-02 2010-04-02
US61/320,577 2010-04-02
PCT/JP2011/001909 WO2011122022A1 (en) 2010-04-02 2011-03-30 Ect2 peptides and vaccines including the same

Publications (3)

Publication Number Publication Date
JP2013523082A JP2013523082A (ja) 2013-06-17
JP2013523082A5 true JP2013523082A5 (enExample) 2014-05-15
JP5816965B2 JP5816965B2 (ja) 2015-11-18

Family

ID=44711777

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012543839A Active JP5816965B2 (ja) 2010-04-02 2011-03-30 Ect2ペプチドおよびそれを含むワクチン

Country Status (20)

Country Link
US (1) US8951975B2 (enExample)
EP (1) EP2553096B1 (enExample)
JP (1) JP5816965B2 (enExample)
KR (1) KR101863557B1 (enExample)
CN (1) CN102939379B (enExample)
AR (1) AR081065A1 (enExample)
AU (1) AU2011233401B2 (enExample)
BR (1) BR112012024997B1 (enExample)
CA (1) CA2795318C (enExample)
CO (1) CO6571869A2 (enExample)
DK (1) DK2553096T3 (enExample)
EA (1) EA027940B1 (enExample)
ES (1) ES2655437T3 (enExample)
IL (1) IL222057A (enExample)
MX (1) MX342000B (enExample)
NZ (1) NZ603379A (enExample)
SG (1) SG184165A1 (enExample)
TW (2) TWI538685B (enExample)
WO (1) WO2011122022A1 (enExample)
ZA (1) ZA201207342B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507719D0 (en) * 2015-05-06 2015-06-17 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
GB201517538D0 (en) * 2015-10-05 2015-11-18 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers
PH12022551111A1 (en) 2015-10-05 2023-08-23 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against small cell lung cancer and other cancers

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239102A3 (en) 1986-03-28 1989-07-12 Tsuji, Kimiyoshi Process for the formation of human-human hybridoma
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
EP0841945B1 (en) 1995-08-03 2006-03-08 Rijksuniversiteit te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
JP2000516090A (ja) 1996-07-26 2000-12-05 スローン―ケッタリング インスティチュート フォー キャンサー リサーチ 遺伝子的免疫化のための方法と試薬
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7393663B2 (en) * 1997-08-01 2008-07-01 Serono Genetics Institute S.A. Expressed sequence tags and encoded human proteins
US20030013649A1 (en) 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
EP1332153A4 (en) * 2000-10-12 2006-01-11 Exelixis Inc HUMAN ECT2 AND METHOD OF USE THEREOF
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7227007B2 (en) * 2000-12-28 2007-06-05 Asahi Kasei Pharma Corporation NF-κB activating gene
EP2336167B1 (en) 2001-03-14 2019-05-29 Dako Denmark A/S MHC molecule constructs and their uses for diagnosis and therapy
US20040236091A1 (en) 2001-03-28 2004-11-25 Chicz Roman M. Translational profiling
WO2002096943A1 (en) * 2001-05-25 2002-12-05 Asahi Kasei Kabushiki Kaisha Stat6-activating genes
US20030092616A1 (en) 2001-05-25 2003-05-15 Akio Matsuda STAT6 activation gene
WO2002099062A2 (en) 2001-06-04 2002-12-12 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
CA2447935A1 (en) * 2001-06-04 2002-12-12 Curagen Corporation Novel antibodies that bind to antigenic polypeptides, nucleic acids encoding the antigens, and methods of use
CA2399569A1 (en) 2001-09-25 2003-03-25 Yusuke Nakamura Diagnostic markers and drug targets for treatment of cancer
GB2392158B (en) 2002-08-21 2005-02-16 Proimmune Ltd Chimeric MHC protein and oligomer thereof
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
JP4614952B2 (ja) 2003-08-20 2011-01-19 オンコセラピー・サイエンス株式会社 腎細胞癌(rcc)の潜在的な新規治療標的としての低酸素誘導タンパク質2(hig2)
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
US7998695B2 (en) 2005-02-10 2011-08-16 Oncotherapy Science, Inc. Method of diagnosing bladder cancer
EP1907582B1 (en) 2005-07-27 2012-01-04 Oncotherapy Science, Inc. Ect2 as a therapeutic target for esophageal cancer
EP2305811A1 (en) 2005-07-27 2011-04-06 Oncotherapy Science, Inc. Method of diagnosing smal cell lung cancer
CN101287831B (zh) 2005-09-13 2013-05-15 国立大学法人三重大学 T细胞受体和编码该受体的核酸
CN101432022A (zh) * 2006-02-28 2009-05-13 肿瘤疗法科学股份有限公司 利用抗-EphA4抗体效应物作用损伤细胞的方法
AU2007311946A1 (en) 2006-10-20 2008-04-24 Forerunner Pharma Research Co., Ltd. Anti-cancer agent comprising anti-HB-EGF antibody as active ingredient
JP5378795B2 (ja) 2006-10-20 2013-12-25 中外製薬株式会社 抗hb−egf抗体を有効成分として含む医薬組成物
TWI494319B (zh) * 2007-02-21 2015-08-01 Oncotherapy Science Inc 表現腫瘤相關抗原之癌症的胜肽疫苗
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
WO2010007791A1 (en) * 2008-07-16 2010-01-21 Oncotherapy Science, Inc. Ect2 oncogene as a therapeutic target and prognostic indicator for lung and esophageal cancer
TW201008574A (en) * 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same

Similar Documents

Publication Publication Date Title
JP2012517799A5 (enExample)
JP2016511221A5 (enExample)
JP2013523084A5 (enExample)
JP2012500001A5 (enExample)
JP2013511958A5 (enExample)
JP2011524737A5 (enExample)
JP2010523471A5 (enExample)
RU2012127358A (ru) Олигопептиды imp-3 и содержащие их вакцины
JP2014519311A5 (enExample)
JP2008530975A5 (enExample)
JP2013517764A5 (enExample)
JP2015529219A5 (enExample)
RU2015143164A (ru) Пептиды kntc2 и содержащие их вакцины
JP2012520659A5 (enExample)
RU2013158399A (ru) Пептиды sema5b и содержащие их вакцины
JP2011522777A5 (enExample)
RU2012136464A (ru) Модифицированные пептиды melk и содержащие их вакцины
RU2014121502A (ru) Пептиды торк и содержащие их вакцины
JP2015524788A5 (enExample)
JP2011529683A5 (enExample)
RU2015113436A (ru) Пептиды ube2t и содержащие их вакцины
RU2014109137A (ru) Пептиды mphosph1 и вакцины, включающие их
JP2014506114A5 (enExample)
JP2012526519A5 (enExample)
JP2014533095A5 (enExample)